Current Market Information

Last Trade Price (LTP) 13.00 Last Trade Date 17 October, 2026 Change -2.24 % Open Price 13.40 Day's Range 13.00 - 13.10     Total Trade 8 Total Volume 11200 Close Price 13.10 Yesterday Close Price 13.40 Market Capital in BDT (mn) 1522.288

Contact Information

Designation Name Mobile Number Email Chairman Mrs. Hafiza Yeasmin 01731936799 hafizaibpl@gmail.com MD A. F. M. Anowarul Huq 01711345816 sabila707@gmail.com CFO Md. Faruque Hossain 01883011125 cfoibpl@gmail.com Company Secretary Mohi Uddin 01777685176 mahfuzdk85@yahoo.com Office Address Plot-183 (7th Floor), Block-B, Ahmed Akber Sobhan Road, Bashundhara R/A, Dhaka-1229. Phone : 09678777995 Fax : Email : info@indo-banglapharma.com Website : http://www.indo-banglapharma.com Factory Address 729, BM College Road, Barishal Sadar, Barishal-8200

Basic Information

Authorized Capital in BDT* (mn) 1,500.00 Paid-up Capital in BDT* (mn) 1,162.05 Face Value 10 Paid up Share 116205178     Market Lot 1 Sector PHARMA & CHEMICALS Market Category B

Other Information

Listing Year 2018 Debut Trade Date 18 October, 2018 Type of Instrument     52 Week's Range 10.50 - 20.90 Year End 30 June Reserve / Surplus(mn) 294.23 Remarks Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 30-Sep, 2026 24.43 0 16.96 0.08 58.53 As on 31-Aug, 2026 24.43 0 17.9 0.08 57.59 As on 31-Jul, 2026 24.43 0 29.45 0 46.12 As on 30-Jun, 2026 (year ended) 24.43 0 31.3 0 44.27     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Nov 06, 2024 BBB ST-3 Stable Nov 25, 2025 Emerging Credit Rating Ltd Nov 06, 2023 BBB ST-3 Stable Nov 05, 2024 Emerging Credit Rating Ltd Nov 06, 2022 BBB ST-3 Stable Nov 05, 2023 Emerging Credit Rating Ltd         Half Year End (HY) Information  202512 HY Net Turnover(mn)  92.03 HY Net Profit after tax(mn)  2.20 HY EPS  0.02  AGM Information   AGM Date  30 December, 2025 Record Date  07 December, 2025 Dividend(%)  0.15 (June 2025) Bonus Issue  3%-2021,2%-2020,9%-2019, 10%-2018

   

Interim Financial Performance: 2026
Particulars	Unaudited / Audited
	Q1	Q2	Half Yearly	Q3	9 Months	Annual
	Ending on	Ending on	6 Months	Ending on		Ending on
	30-Sep-2025	31-Dec-2025	31-Dec-2025	31-Mar-2026		30-Jun-2026
Earnings Per Share (EPS)
Basic	0.010	0.010	0.020	0.010	0.020
Diluted*
Earnings Per Share (EPS) - continuing operations
Basic	0.010	0.010	0.020	0.010	0.020
Diluted*
Market price per share at period end

*As per BSEC Directive No. SEC/CMRRCD/2009-193/64, dated September 21, 2010.

*Note: For detail financial statements, please visit company’s website.

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2025	-0.32	0	0	0	12.53	0	-36.83	0	0.15%	0.11
2024	-0.35	0	0	0	13.6	0	-40.98	0	0.1C%	0.08
2023	0.07	0	0	0	13.96	0	8.41	0		0
2022	0.22	0	0	0	13.98	0	25.17	0	1%C	0.56
2021	1.18	0	0	0	14.29	0	134.73	0	4%C,3%B	2.02

Financial Statements
Quarterly Financial Statement	https://www.indo-banglapharma.com/site/investor?cat=Quarterly Report
Price Sensitive Information	https://www.indo-banglapharma.com/site/investor?cat=PRICE SENSITIVE INFORMATION (PSI)

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To